文献速递泌尿生殖介入MR

机器人辅助经直肠MRI引导活检:技术可行性与在前列腺癌现行诊断中的作用——单中心初步经验

Robotic-assisted transrectal MRI-guided biopsy. Technical feasibility and role in the current diagnosis of prostate cancer: an initial single-center experience.
PubMed 文献 · Abdom Radiol (NY) · 2020-07-23

单中心30例PI-RADSv2.1≥3可疑前列腺癌病灶患者行机器人经直肠MRI遥控引导靶向活检,总体癌检出率73%(22/30),显著肿瘤检出率86%(19/22),活检初治患者检出率89%(16/18)高于既往经直肠超声引导活检阴性者50%(6/12),全部病灶均可到达,结论认为该技术可行、有效,可能有助于显著前列腺癌的诊断。

要点

  • 机器人MRI引导经直肠靶向活检在30例PI-RADS≥3病灶中全部可到达,技术可行。
  • 总体癌检出率73%(22/30),显著肿瘤检出率86%(19/22),Gleason>6肿瘤检出率77%(17/22)。
  • 活检初治患者癌检出率89%(16/18),既往经直肠超声引导活检阴性者50%(6/12)。

核心结论

  • 初步数据显示机器人MRI引导活检在当前显著前列腺癌诊断新范式中可能有用、高效且可行,适用于经过选择的患者。

研究设计与样本

  • 单中心初步经验,30例MRI判读为PI-RADSv2.1≥3的单一可疑癌病灶患者接受机器人经直肠MRI遥控引导活检,分析技术成功、临床资料、活检结果与MRI的对应关系、并发症及癌检出率。

关键影像表现/征象

  • 全部30个病灶均可被机器人MRI设备到达。
  • 报告1例自限性直肠出血并发症。

诊断标准与关键数值

  • 总体任何癌检出率为73%(22/30)。
  • 显著肿瘤(Gleason评分>6,或Gleason 6时最大癌核心长度>3 mm)检出率为86%(19/22)。
  • Gleason>6肿瘤检出率为77%(17/22)。
  • 活检初治患者癌检出率为89%(16/18),既往经直肠超声引导活检阴性患者为50%(6/12)。
  • PI-RADS>3病灶的癌检出率为92%(22/24)。

临床应用与阅片要点

  • 作者认为机器人MRI引导活检在经选择患者中可能是有用、高效且可行的显著前列腺癌诊断方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the potential clinical and technical utility to manage in practice the use of a robotic MRI in-bore-targeted prostate biopsies in the current work-up of prostate cancer diagnosis.

METHODS: Thirty patients with a single cancer suspicious lesion interpreted on MRI using PI-RADSv2.1 category ≥ 3 underwent in-bore robotic transrectal MRI remote-controlled-guided biopsy. It was analyzed the technical success, clinical details, biopsy findings in correlation with the MRI examination, complications and cancer detection rate (CDR).

RESULTS: The overall CDR for any cancer was 73% (22/30). It was 86% (19/22) for significant tumors (Gleason score of more than 6 or maximum cancer core length greater than 3 mm for Gleason 6) and 77% (17/22) for tumors with Gleason > 6. CDR for biopsy-naïve patients was 89% (16/18) and 50% (6/12) for patients with prior negative transrectal ultrasound-guided biopsies. The CDR for PI-RADS > 3 was 92% (22/24). All the lesions (n = 30) were reachable with the robotic MRI device. A self-limited rectal hemorrhagic complication was reported.

CONCLUSION: This initial data show that a robotic MRI-guided biopsy could be useful, efficient and feasible procedure in the new paradigm to diagnose significant prostate cancer in selected patients.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Vilanova JC, Pérez de Tudela A, Puig J, et al. Robotic-assisted transrectal MRI-guided biopsy. Technical feasibility and role in the current diagnosis of prostate cancer: an initial single-center experience. Abdom Radiol (NY). 2020. PMID: 32705314. doi:10.1007/s00261-020-02665-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。